Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease.

Papamichael, Konstantinos; Vande Casteele, Niels; Abraham, Bincy P; Ritter, Timothy; Jain, Anjali; Cheifetz, Adam S

Papamichael, Konstantinos; Vande Casteele, Niels; Abraham, Bincy P; Ritter, Timothy; Jain, Anjali; Cheifetz, Adam S.

Afiliación

Papamichael K; Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts. Electronic address: kpapamic@bidmc.harvard.edu.
Vande Casteele N; Department of Medicine, University of California San Diego, La Jolla, California.
Abraham BP; Department of Medicine, Houston Methodist Hospital, Houston, Texas.
Ritter T; GI Alliance Research, Southlake, Texas.
Jain A; Prometheus Laboratories, San Diego, California.
Cheifetz AS; Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Clin Gastroenterol Hepatol ; 21(11): 2978-2980.e2, 2023 10.

Article en En | MEDLINE | ID: mdl-36372372

Asunto(s)

Colitis Ulcerosa; Enfermedades Inflamatorias del Intestino; Humanos; Adalimumab/efectos adversos; Infliximab/efectos adversos; Anticuerpos Monoclonales Humanizados/uso terapéutico; Enfermedades Inflamatorias del Intestino/tratamiento farmacológico; Factor de Necrosis Tumoral alfa

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Colitis Ulcerosa Límite: Humans Idioma: En Revista: Clin Gastroenterol Hepatol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google